Kyverna Therapeutics (KYTX) Other Accumulated Expenses (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Other Accumulated Expenses came in at $3.0 million in Q1 2026, up 71.94% YoY from $1.8 million in Q1 2025, and up 39.15% on a QoQ basis from $2.2 million in Q4 2025.
Kyverna Therapeutics (KYTX) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Other Accumulated Expenses data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Other Accumulated Expenses rose 71.94% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 71.94% YoY) and the FY2025 annual result came in at $2.2 million, down 25.22% from the prior year.
- Other Accumulated Expenses improved to $3.0 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $3.0 million in Q1 2026 to a low of $1.2 million in Q2 2025.
- A 4-year average of $2.1 million and a median of $2.0 million in 2025 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Other Accumulated Expenses retreated 25.22% — and 2026, when it jumped 71.94%.
- Tracing KYTX's Other Accumulated Expenses over 4 years: stood at $1.8 million in 2023, then soared by 62.27% to $2.9 million in 2024, then dropped by 25.22% to $2.2 million in 2025, then soared by 39.15% to $3.0 million in 2026.
- The last three Other Accumulated Expenses figures came in at $3.0 million (Q1 2026), $2.2 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | 3.02 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 2.04 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 1.79 Mn |